Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Indices offer a practical way to quantify risk exposure and monitor changes over time, supporting proactive adjustments.
27,018 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Investors weigh whether the next policy move could target Cuba after Venezuela and Iran, a shift that could ripple th...
A major investment firm just snapped up a sizable stake in Integer Holdings as its shares slide. Learn what this coul...
A large insider stake reduction coincided with Boise Cascade stock down, prompting questions about valuation and risk...
Institutional moves shape the AI stock landscape. This article dives into Philippe Laffont’s Coatue strategy, why Nvi...
Lululemon posted a mixed quarter: international sales led growth while the core US market softened. This analysis dig...
A prominent investment firm stepped into Black Hills Corporation, driving a 22% gain over the year. This article brea...
As SpaceX edges toward a trillion-dollar valuation, wealth managers confront a new scale of risk. A single misstep ca...
Dividend-focused ETFs remain a fixture for retirement income, but a shifting rate landscape tests how long these fund...
A disciplined $500 monthly investment into a semiconductor-focused ETF since 2016 would have climbed to roughly half ...
A new AI-focused ETF from Wedbush-backed manager Dan Ives is drawing attention for its blend of megacap AI leaders an...
A thousand dollars can start a disciplined plan in uncertain markets. Learn where to put $1,000 when market is uncert...